Last reviewed · How we verify

Isobaric 2-chloroprocaine

Centre Hospitalier Universitaire Saint Pierre · FDA-approved active Small molecule

Isobaric 2-chloroprocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.

Isobaric 2-chloroprocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission. Used for Local and regional anesthesia for surgical procedures, Intrathecal anesthesia for spinal procedures.

At a glance

Generic nameIsobaric 2-chloroprocaine
Also known asAmpres, Ampres 10mg/ml
SponsorCentre Hospitalier Universitaire Saint Pierre
Drug classLocal anesthetic (ester)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

As a local anesthetic agent, 2-chloroprocaine works by inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and conduction of action potentials. The isobaric formulation is designed to have a specific gravity matching cerebrospinal fluid, allowing for controlled distribution when administered intrathecally. This enables localized anesthesia with predictable spread and duration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: